

John Stagg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1357141/publications.pdf>

Version: 2024-02-01

61
papers

8,268
citations

109264

35
h-index

133188

59
g-index

63
all docs

63
docs citations

63
times ranked

9351
citing authors

#	ARTICLE	IF	CITATIONS
1	The ectonucleotidases <scp>CD</scp>39 and <scp>CD</scp>73: Novel checkpoint inhibitor targets. Immunological Reviews, 2017, 276, 121-144.	2.8	637
2	Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science, 2020, 369, 1481-1489.	6.0	635
3	Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1547-1552.	3.3	492
4	Anti-€ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-€PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7142-7147.	3.3	413
5	CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11091-11096.	3.3	406
6	Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. Clinical Cancer Research, 2013, 19, 5626-5635.	3.2	381
7	CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis. Cancer Research, 2011, 71, 2892-2900.	0.4	353
8	CD73: a potent suppressor of antitumor immune responses. Trends in Immunology, 2012, 33, 231-237.	2.9	310
9	Blockade of A _{2A} receptors potently suppresses the metastasis of CD73 ⁺ tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14711-14716.	3.3	306
10	The adenosine pathway in immuno-oncology. Nature Reviews Clinical Oncology, 2020, 17, 611-629.	12.5	275
11	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. Journal of Clinical Investigation, 2019, 129, 1785-1800.	3.9	266
12	Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-€PD-1 through Enhanced Antitumor T-cell Responses. Cancer Immunology Research, 2015, 3, 506-517.	1.6	262
13	Targeting Cancer-Derived Adenosine:New Therapeutic Approaches. Cancer Discovery, 2014, 4, 879-888.	7.7	256
14	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. Journal of Clinical Investigation, 2017, 127, 929-941.	3.9	251
15	Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor. Cancer Research, 2014, 74, 3652-3658.	0.4	217
16	Immunosuppressive activities of adenosine in cancer. Current Opinion in Pharmacology, 2016, 29, 7-16.	1.7	216
17	CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancer Research, 2015, 75, 4494-4503.	0.4	186
18	CD73-Deficient Mice Are Resistant to Carcinogenesis. Cancer Research, 2012, 72, 2190-2196.	0.4	178

#	ARTICLE	IF	CITATIONS
19	CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 158-166.	3.2	156
20	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 169-181.	1.4	149
21	Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. <i>Annals of Oncology</i> , 2018, 29, 1056-1062.	0.6	138
22	Anti-CD73 therapy impairs tumor angiogenesis. <i>International Journal of Cancer</i> , 2014, 134, 1466-1473.	2.3	135
23	Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. <i>Cancer Research</i> , 2016, 76, 4372-4382.	0.4	130
24	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. <i>Journal of the National Cancer Institute</i> , 2020, 112, 708-719.	3.0	111
25	CD73-adenosine: a next-generation target in immuno-oncology. <i>Immunotherapy</i> , 2016, 8, 145-163.	1.0	110
26	Targeting the CD73-adenosine axis in immuno-oncology. <i>Immunology Letters</i> , 2019, 205, 31-39.	1.1	106
27	Targeting A2 adenosine receptors in cancer. <i>Immunology and Cell Biology</i> , 2017, 95, 333-339.	1.0	91
28	CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. <i>Cancer Research</i> , 2017, 77, 5652-5663.	0.4	90
29	Mesenchymal Stem Cells in Cancer. <i>Stem Cell Reviews and Reports</i> , 2008, 4, 119-124.	5.6	85
30	On the mechanism of anti-CD39 immune checkpoint therapy. , 2020, 8, e000186.		82
31	CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-8.	3.0	80
32	From cancer immunosurveillance to cancer immunotherapy. <i>Immunological Reviews</i> , 2007, 220, 82-101.	2.8	78
33	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31802.	3.6	70
34	Targeting the adenosine pathway for cancer immunotherapy. <i>Seminars in Immunology</i> , 2019, 42, 101304.	2.7	60
35	Spatially mapping the immune landscape of melanoma using imaging mass cytometry. <i>Science Immunology</i> , 2022, 7, eabi5072.	5.6	60
36	1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer. <i>Science Advances</i> , 2021, 7, .	4.7	46

#	ARTICLE	IF	CITATIONS
37	Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16254-16259.	3.3	45
38	CD73-adenosine reduces immune responses and survival in ovarian cancer patients. Oncoimmunology, 2016, 5, e1127496.	2.1	38
39	Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opinion on Therapeutic Targets, 2014, 18, 863-881.	1.5	37
40	CD73 Plays a Protective Role in Collagen-Induced Arthritis. Journal of Immunology, 2015, 194, 2487-2492.	0.4	34
41	Polyl:C and CpG Synergize with Anti-ErbB2 mAb for Treatment of Breast Tumors Resistant to Immune Checkpoint Inhibitors. Cancer Research, 2017, 77, 312-319.	0.4	28
42	WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. Oncoimmunology, 2019, 8, e1581545.	2.1	28
43	Targeting an adenosine-mediated A_2A receptor signal augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia, 2020, 34, 2708-2721.	3.3	27
44	Adenosine A_2A receptor promotes lymphangiogenesis and lymph node metastasis. Oncoimmunology, 2019, 8, 1601481.	2.1	24
45	The double-edge sword effect of anti-CD73 cancer therapy. Oncoimmunology, 2012, 1, 217-218.	2.1	23
46	Co-blockade of immune checkpoints and adenosine A_2A receptor suppresses metastasis. Oncoimmunology, 2014, 3, e958952.	2.1	22
47	Prognostic value of CD73 expression in resected colorectal cancer liver metastasis. Oncoimmunology, 2020, 9, 1746138.	2.1	22
48	NK Cell-Based Cancer Immunotherapy. Drug News and Perspectives, 2007, 20, 155.	1.9	18
49	High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer. , 2021, 9, e001965.		16
50	IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. Cancer Discovery, 2022, 12, 1960-1983.	7.7	14
51	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. Breast Care, 2012, 7, 267-272.	0.8	12
52	The effect of ultrasound pulse length on microbubble cavitation induced antibody accumulation and distribution in a mouse model of breast cancer. Nanotheranostics, 2020, 4, 256-269.	2.7	12
53	NR4A Expression by Human Marginal Zone B-Cells. Antibodies, 2019, 8, 50.	1.2	10
54	Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns. British Journal of Cancer, 2022, 126, 1329-1338.	2.9	10

#	ARTICLE	IF	CITATIONS
55	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. <i>Methods in Molecular Biology</i> , 2016, 1458, 159-177.	0.4	7
56	Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays. <i>Methods in Enzymology</i> , 2019, 629, 269-289.	0.4	6
57	CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination. <i>PLoS ONE</i> , 2018, 13, e0191973.	1.1	3
58	Abstract 3361: CD73 expression on tumor-infiltrating breast cancer leukocytes. <i>Cancer Research</i> , 2015, 75, 3361-3361.	0.4	3
59	CD73 Promotes Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 3130.	1.7	3
60	Prognostic value of CD73 expression in resected colorectal cancer liver metastasis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3584-3584.	0.8	2
61	Immunology and Immunotherapy of Breast Cancer. , 2015, , 457-470.		0